DEVONIAN HEALTH GROUP INC Stock Price, News & Analysis

Devonian Health Group (OTCQB: DVHGF) announced on December 4, 2025 the publication of a peer-reviewed article in Biomedicines titled "Thykamine™: A New Player in the Field of Anti-Inflammatory Drugs." Researchers compared Thykamine™ with six widely prescribed anti-inflammatory drugs in an in vitro immune-activated cell model and reported that Thykamine™ inhibited MCP-1, MIP-1α and MIP-1β with greater potency than all comparators and suppressed RANTES comparable or superior to most agents tested. Effects occurred at lower concentrations and with no detectable cytotoxicity, suggesting a favorable tolerability profile and potential for further therapeutic development targeting chronic inflammatory and fibrotic conditions.

Devonian Health Group (OTCQB: DVHGF) reported fourth-quarter and fiscal 2025 results for the year ended July 31, 2025. Key metrics: Q4 distribution revenue $1.3M (down 87% YoY), FY distribution revenue $23.6M (up 22% YoY), Q4 net loss $0.375M ($0.003/share), and FY net loss $6.0M ($0.041/share). The FY loss included a $4.6M goodwill impairment and $0.2M IP impairment. R&D spending rose to $2.0M (up 55.8%) to support Thykamine pediatric phase 2/3 and preclinical work. The corporation is debt free after repaying $2.2M and held $7.0M cash at July 31, 2025. Pierre Labbé was appointed to the board.

Devonian Health Group (OTCQB: DVHGF), a clinical-stage biopharmaceutical company, provided updates on multiple fronts. The company reported significant progress with its flagship drug Thykamine™, validating batch-to-batch consistency through advanced analytical techniques and advancing pre-clinical programs in MASH and pulmonary fibrosis, with data expected in fall 2025.

The company is developing oral formulations for Thykamine™ and received positive U.S. dermatologist survey results for pediatric atopic dermatitis applications. Additionally, Devonian announced the upcoming termination of its Pantoprazole Magnesium distribution agreement in April 2026, which represented 10.6% of FY2024 revenues and 4.2% of revenue for the nine months ended April 2025.

The company also corrected details of its recent private placement, noting total gross proceeds of $2.36 million through the issuance of 15.75 million units at $0.15 per unit, each including one share and one warrant exercisable at $0.20 for 24 months.

Devonian Health Group (OTCQB: DVHGF), a clinical-stage company focused on inflammatory disease solutions, has completed a non-brokered private placement raising $2.27 million in gross proceeds. The offering consisted of 15,153,332 units priced at $0.15 per unit, with each unit comprising one subordinate voting share and one warrant.

Each warrant allows holders to purchase one share at $0.20 within a 24-month period. The funds will support working capital needs, corporate overhead, and R&D activities. The securities have a four-month restricted hold period ending December 8, 2025.

Devonian Health Group (OTCQB:DVHGF) reported its Q3 2025 financial results, with revenue increasing 36% year-over-year to $7.36 million. The company recorded a net loss of $0.032 per share, primarily due to a $4.84 million non-cash impairment loss related to the expiration of their DEXLANSOPRAZOLE distribution agreement.

The quarter saw significant management changes with Dr. Andre Boulet appointed as CEO and Luc Gregoire as Executive Vice-President Strategy. The company completed preclinical studies for Thykamine™, exploring new applications in inflammatory diseases, including MASH and fibrosis.

Devonian Health Group (OTCQB: DVHGF), a clinical-stage company focused on inflammatory diseases, has announced key leadership changes and stock option grants. Dr. André Boulet has been appointed as Chief Executive Officer, replacing Luc Gregoire who transitions to Executive Vice-President Strategy, effective June 9, 2025. The company also granted stock options totaling 1,288,596 shares at an exercise price of $0.15, valid until June 9, 2035. Of these, 438,596 options were granted to a director and 850,000 to employees. The options follow a vesting schedule with 50.33% immediately exercisable, and the remaining portions vesting over 48 months in equal installments of 12.42% every 12 months.

Devonian Health Group has successfully achieved reinstatement of its common shares trading on the TSX Venture Exchange (TSXV), effective April 30, 2025. This development follows the resolution of a temporary trading suspension.

Key developments:

• The Autorité des marchés financiers (AMF) issued a Failure-to-File Cease Trade Order on April 7, 2025
• The suspension was due to delayed filing of required interim financial documents for the quarter ending January 31, 2025
• Company submitted the required filings on April 15, 2025
• AMF revoked the cease trade order on April 16, 2025

The required submissions included quarterly financial statements, management's discussion and analysis, and related documentation. Trading will resume under the symbols GSD on TSXV and DVHGF on OTCQB. The company has expressed gratitude to shareholders for their patience and reinforced its dedication to maintaining high compliance standards.

Devonian Health Group (OTCQB: DVHGF) reported strong Q2 2025 financial results with revenue soaring 275% year-over-year to $8.28 million, primarily driven by DEXLANSOPRAZOLE distribution agreement. The company posted a net loss of $0.001 per share, improving from $0.01 loss per share in the previous year.

The company's cash position stood at $8.4 million with zero debt, down from $9.9 million at fiscal year start. Notable achievements include Thykamine™'s superior performance in anti-inflammatory studies versus corticosteroids, positive results in MASH mouse model studies, and new provisional patent applications for Thykamine™ in metabolic dysfunction-associated steatohepatitis and as an anti-fibrotic agent.

Devonian Health Group (TSXV: GSD; OTCQB: DVHGF) has received a failure to file cease trade order (FFCTO) from the Autorité des Marchés Financiers (AMF) due to delayed filing of required interim financial documents for the period ended January 31, 2025.

The FFCTO prohibits all trading of company securities in Canada, including trades through the TSX Venture Exchange. The required documents include interim financial statements, management's discussion and analysis, and related filings that were due by April 1, 2025.

Trading suspension became effective April 8, 2025. The company continues normal business operations and will seek FFCTO revocation once the required filings are submitted. Trading reinstatement requires both FFCTO revocation and Exchange approval following a compliance review.